Zoledronsyra

Klassificering: A

Preparat: Aclasta®, Zerlinda, Zoledronic Acid Accord, Zoledronic acid Actavis, Zoledronic Acid Fresenius Kabi, Zoledronic Acid Hospira, Zoledronic acid Mylan, Zoledronic Acid Teva, Zoledronsyra Hameln, Zoledronsyra medac, Zoledronsyra STADA, Zoledronsyra SUN, Zometa®

ATC kod: M05BA08

Substanser: zoledronsyra, zoledronsyrahemipentahydrat, zoledronsyramonohydrat, zoledronsyratrihydrat

Sammanfattning

Bisfosfonater ökar benmineraltätheten (BMD) lika effektivt hos både män och kvinnor, vilket medför lägre risk för benfraktur.

Kunskapsunderlaget avseende skillnader mellan kvinnor och män är begränsat och motiverar inte olika dosering eller behandling.

Additional information

Pharmacokinetics and dosing

The total body clearance of zoledronic acid is 5.04 ± 2.5 L/hour, independent of dose, and unaffected by sex, age, body weight and race. The clinical studies have shown effect with similar doses in men and women and no sex differentiation in dosing has been suggested [1].

Effects

A post hoc analysis (265 men, 568 women) evaluated the effects of a single dose of IV zoledronic acid 5 mg versus oral risedronate 5 mg/day on lumbar spine BMD. Zoledronic acid treated patients had a higher increase in lumbar spine BMD in both men and women at month 12 compared to risedronate [2].

Adverse effects

No studies with a clinically relevant sex analysis regarding adverse effects of zoledronic acid have been found.

Reproductive health issues

Regarding teratogenic aspects, please consult the Drugs and Birth Defects Database (in Swedish, Janusmed fosterpåverkan).

Försäljning på recept

Infusionsvätska innehållande zoledronsyra (ATC-kod M05BA08) används huvudsakligen på sjukhus och därför saknas könsspecifika användningsdata [3].

Uppdaterat: 2019-02-26

Litteratursökningsdatum: 2014-08-06

Referenser

ZOMETA (zoledronic acid). Summary of Product Characteristics. European Medicines Agency (EMA); 2014.
Roux C, Reid DM, Devogelaer JP, Saag K, Lau CS, Reginster JY et al. Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis. Osteoporos Int. 2012;23:1083-90. PubMed
Conicse. Stockholm: eHälsomyndigheten. 2015 [cited 2016-03-23.] länk

Författare: Linnéa Karlsson Lind, Desirée Loikas

Faktagranskat av: Mia von Euler

Godkänt av: Karin Schenck-Gustafsson